I am a
Home I AM A Search Login

Papers of the Week

2022 Jun 23

Expert Opin Drug Saf

Safety profile of lasmiditan in patients with migraine in an Asian population.


Hirata K, Matsumori Y, Tanji Y, Khanna R, Ozeki A, Komori M
Expert Opin Drug Saf. 2022 Jun 23.
PMID: 35736027.


MONONOFU, a multicenter, randomized, double-blind, placebo-controlled phase 2 study of Japanese patients with migraine, was pivotal for lasmiditan approval in Japan. However, treatment-emergent adverse events (TEAEs) were more common than in global studies. A detailed safety profile would assist patient management.